FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2967113395> ?p ?o ?g. }

• W2967113395 endingPage "2999" @default.
• W2967113395 startingPage "2987" @default.
• W2967113395 abstract "PURPOSE Metastatic mucosal melanoma responds poorly to anti–programmed cell death-1 (PD-1) monotherapy. Vascular endothelial growth factor (VEGF) has been shown to play an important immunosuppressive role in the tumor microenvironment. The combination of VEGF inhibition and PD-1 blockade provides therapeutic opportunities for patients refractory to either therapy alone. PATIENTS AND METHODS We conducted a single-center, phase IB trial evaluating the safety and preliminary efficacy of toripalimab, a humanized immunoglobulin G 4 monoclonal antibody against PD-1 in combination with the VEGF receptor inhibitor axitinib in patients with advanced melanoma, including patients with chemotherapy-naïve mucosal melanomas (88%). Patients received toripalimab at 1 or 3 mg/kg via intravenous infusion every 2 weeks, in combination with axitinib 5 mg orally twice a day, in a dose-escalation and cohort-expansion study until confirmed disease progression, unacceptable toxicity, or voluntary withdrawal. The primary objective was safety. Secondary objectives included efficacy, pharmacokinetics, pharmacodynamics, immunogenicity, and tumor tissue biomarkers. RESULTS Thirty-three patients were enrolled. No dose-limiting toxicities were observed. Ninety-seven percent of patients experienced treatment-related adverse events (TRAEs). The most common TRAEs were mild (grade 1 or 2) and included diarrhea, proteinuria, hand and foot syndrome, fatigue, AST or ALT elevation, hypertension, hypo- or hyperthyroidism, and rash. Grade 3 or greater TRAEs occurred in 39.4% of patients. By the cutoff date, among 29 patients with chemotherapy-naïve mucosal melanoma, 14 patients (48.3%; 95% CI, 29.4% to 67.5%) achieved objective response, and the median progression-free survival time was 7.5 months (95% CI, 3.7 months to not reached) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CONCLUSION The combination of toripalimab plus axitinib was tolerable and showed promising antitumor activity in patients with treatment-naïve metastatic mucosal melanoma. Patients enrolled in this study were all Asian, and this combination therapy must be validated in a randomized phase III trial that includes a non-Asian population before it can become a standard of care." @default.
• W2967113395 created "2019-08-22" @default.
• W2967113395 creator A5005126432 @default.
• W2967113395 creator A5006251921 @default.
• W2967113395 creator A5007348590 @default.
• W2967113395 creator A5007562507 @default.
• W2967113395 creator A5009201250 @default.
• W2967113395 creator A5018372804 @default.
• W2967113395 creator A5023174631 @default.
• W2967113395 creator A5034855042 @default.
• W2967113395 creator A5035685296 @default.
• W2967113395 creator A5047115795 @default.
• W2967113395 creator A5047774145 @default.
• W2967113395 creator A5055356574 @default.
• W2967113395 creator A5062012068 @default.
• W2967113395 creator A5062637798 @default.
• W2967113395 creator A5068116429 @default.
• W2967113395 creator A5068605395 @default.
• W2967113395 creator A5069813415 @default.
• W2967113395 creator A5073531557 @default.
• W2967113395 creator A5077722053 @default.
• W2967113395 creator A5078973363 @default.
• W2967113395 creator A5084636770 @default.
• W2967113395 creator A5087476818 @default.
• W2967113395 date "2019-11-10" @default.
• W2967113395 modified "2023-10-11" @default.
• W2967113395 title "Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G₄ Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial" @default.
• W2967113395 cites W130026146 @default.
• W2967113395 cites W1518184777 @default.
• W2967113395 cites W1545177819 @default.
• W2967113395 cites W1989121777 @default.
• W2967113395 cites W1989182836 @default.
• W2967113395 cites W2000463365 @default.
• W2967113395 cites W2068237418 @default.
• W2967113395 cites W2078616035 @default.
• W2967113395 cites W2096223992 @default.
• W2967113395 cites W2099200814 @default.
• W2967113395 cites W2103152130 @default.
• W2967113395 cites W2103549763 @default.
• W2967113395 cites W2104096707 @default.
• W2967113395 cites W2109092551 @default.
• W2967113395 cites W2142506385 @default.
• W2967113395 cites W2143963425 @default.
• W2967113395 cites W2147474070 @default.
• W2967113395 cites W2149678643 @default.
• W2967113395 cites W2156266404 @default.
• W2967113395 cites W2156906256 @default.
• W2967113395 cites W2257628051 @default.
• W2967113395 cites W2330679970 @default.
• W2967113395 cites W2546302461 @default.
• W2967113395 cites W2549481046 @default.
• W2967113395 cites W2553340100 @default.
• W2967113395 cites W2563871566 @default.
• W2967113395 cites W2599048038 @default.
• W2967113395 cites W2611187032 @default.
• W2967113395 cites W2613188317 @default.
• W2967113395 cites W2655262992 @default.
• W2967113395 cites W2784063247 @default.
• W2967113395 cites W2785838318 @default.
• W2967113395 cites W2796223827 @default.
• W2967113395 cites W2800160190 @default.
• W2967113395 cites W2805302875 @default.
• W2967113395 cites W2884949281 @default.
• W2967113395 cites W2897815318 @default.
• W2967113395 cites W2909679049 @default.
• W2967113395 cites W2923110622 @default.
• W2967113395 cites W60508422 @default.
• W2967113395 doi "https://doi.org/10.1200/jco.19.00210" @default.
• W2967113395 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6839911" @default.
• W2967113395 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31403867" @default.
• W2967113395 hasPublicationYear "2019" @default.
• W2967113395 type Work @default.
• W2967113395 sameAs 2967113395 @default.
• W2967113395 citedByCount "112" @default.
• W2967113395 countsByYear W29671133952019 @default.
• W2967113395 countsByYear W29671133952020 @default.
• W2967113395 countsByYear W29671133952021 @default.
• W2967113395 countsByYear W29671133952022 @default.
• W2967113395 countsByYear W29671133952023 @default.
• W2967113395 crossrefType "journal-article" @default.
• W2967113395 hasAuthorship W2967113395A5005126432 @default.
• W2967113395 hasAuthorship W2967113395A5006251921 @default.
• W2967113395 hasAuthorship W2967113395A5007348590 @default.
• W2967113395 hasAuthorship W2967113395A5007562507 @default.
• W2967113395 hasAuthorship W2967113395A5009201250 @default.
• W2967113395 hasAuthorship W2967113395A5018372804 @default.
• W2967113395 hasAuthorship W2967113395A5023174631 @default.
• W2967113395 hasAuthorship W2967113395A5034855042 @default.
• W2967113395 hasAuthorship W2967113395A5035685296 @default.
• W2967113395 hasAuthorship W2967113395A5047115795 @default.
• W2967113395 hasAuthorship W2967113395A5047774145 @default.
• W2967113395 hasAuthorship W2967113395A5055356574 @default.
• W2967113395 hasAuthorship W2967113395A5062012068 @default.
• W2967113395 hasAuthorship W2967113395A5062637798 @default.
• W2967113395 hasAuthorship W2967113395A5068116429 @default.
• W2967113395 hasAuthorship W2967113395A5068605395 @default.
• W2967113395 hasAuthorship W2967113395A5069813415 @default.
• W2967113395 hasAuthorship W2967113395A5073531557 @default.

• next